# Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/afatinib-is-effective-in-the-treatment-of-lung-adenocarcinoma-with-uncommon-egfr/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sheng‐Kai Liang,Jen‐Chung Ko,James Chih‐Hsin Yang,Jin‐Yuan Shih |
| Citations | 46 |
| DOI | 10.1016/j.lungcan.2019.05.019 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2946204770 |
| PMID | 31200815 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Sheng‐Kai Liang](https://scholariq.org/researchers/sheng-kai-liang/)

## Paper journal

- [Lung Cancer](https://scholariq.org/journals/lung-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.